O ne reason for the 2010 drug price increases, and those we will likely experience in the future, is the shortfall in revenue from the loss of patent protection from drugs with high global sales. The annual company sales at risk from patent expiration have risen from approximately $12 billion in 2006 to over $30 billion in 2012.
Additional agents with estimated patent expirations in 2012 include Lexapro, Symbicort, Avandia, Diovan, Provigil, Crestor, Zometa, and Geodon. This list is not meant to be complete, only to indicate the fact that agents with significant formulary status will be affected. The patent expiration process is also quite fluid; anticipated patent expiration dates may change.
Pfizer and Eli Lilly have the largest percentage of their portfolio at risk within the next 3 years, both with nearly two-thirds of their portfolios likely to meet generic competition. Pfizer's loss of Lipitor will allow Novartis to claim the title of world's largest drug house. Eli Lilly will face similar difficulty in responding to shareholders.
Due to several considerations regarding patent protection, generic versions are not always available immediately after a patent expires, however we should expect an increasing number of expirations resulting in generic availability. The pharmaceutical industry faces significant cost pressure to maximize revenue prior to an individual drug's expiration and increase pricing along a company's product line. Pharmaceutical companies have been preparing for this patent cliff for some time through selective price increases, cost reduction, and pipeline enrichment. We should expect significant increases in the future.
This brings us to the opportunity we should not overlook, the formulary. Even for large and integrated health care systems, the formulary management function of many Pharmacy & Therapeutics Committees tends to take a forward-looking approach.
These committees primarily focus on agents recently approved by the US Food and Drug Administration and how new agents compare with currently available agents. Clinical efficacy, safety, and cost are the primary drivers of formulary adoption. Due to cost reductions that should be expected from increased generic availability, it may be time to review drug classes on the formulary that have not been considered for some time. Because pricing is largely contract driven in the hospital market, I encourage you to work closely with your group purchasing organization to guarantee that new manufacturer contracts and contracting bundles truly pass down the savings for new generic availability.
